The behavioural and electrophysiological effects of CRF in rat frontal cortex. 2008

Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna Street 12, 31-343 Cracow, Poland. zieba.bmt@wp.pl

Corticotropin releasing factor (CRF) is a neuropeptide widely distributed in the brain. The role of CRF in the behavioural activity and modulation of anxiety states in several brain structures has been well documented, but its function in the cerebral cortex still remains unknown. The aim of our study was to investigate the effect of CRF injected bilaterally into rat frontal cortex on the locomotor and exploratory activity and anxiety of rats. We also examined the effect of CRF on extracellularly recorded field potentials in rat frontal cortical slices in vitro. Behavioural experiments showed that CRF in doses of 0.05, 0.1, 0.2 microg/1 microl/site decreased locomotor and exploratory activity during a 40-min session in the open field test. In the elevated plus-maze test, CRF in a dose of 0.2 microg/1 microl/site produced a significant anxiolytic-like effect, which was prevented by CRF receptor antagonists (alpha-helicalCRF(9-41) and NBI 27914). Electrophysiological experiments showed that CRF-induced a transient depression of field potentials in slices partly disinhibited by GABA(A) and GABA(B) receptors antagonists. The blockade of NMDA receptors prevented the occurrence of that effect. The obtained results suggest that CRF may have anxiolytic-like effects in the frontal cortex. Moreover, the peptide inhibits locomotor and exploratory activity and depresses excitatory synaptic transmission in a NMDA receptor-dependent manner.

UI MeSH Term Description Entries
D008297 Male Males
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D003346 Corticotropin-Releasing Hormone A peptide of about 41 amino acids that stimulates the release of ADRENOCORTICOTROPIC HORMONE. CRH is synthesized by neurons in the PARAVENTRICULAR NUCLEUS of the HYPOTHALAMUS. After being released into the pituitary portal circulation, CRH stimulates the release of ACTH from the PITUITARY GLAND. CRH can also be synthesized in other tissues, such as PLACENTA; ADRENAL MEDULLA; and TESTIS. ACTH-Releasing Hormone,CRF-41,Corticotropin-Releasing Factor,Corticotropin-Releasing Hormone-41,ACTH-Releasing Factor,CRF (ACTH),Corticoliberin,Corticotropin-Releasing Factor-41,ACTH Releasing Factor,ACTH Releasing Hormone,Corticotropin Releasing Factor,Corticotropin Releasing Factor 41,Corticotropin Releasing Hormone,Corticotropin Releasing Hormone 41
D004594 Electrophysiology The study of the generation and behavior of electrical charges in living organisms particularly the nervous system and the effects of electricity on living organisms.
D005625 Frontal Lobe The part of the cerebral hemisphere anterior to the central sulcus, and anterior and superior to the lateral sulcus. Brodmann Area 8,Brodmann's Area 8,Frontal Cortex,Frontal Eye Fields,Lobus Frontalis,Supplementary Eye Field,Area 8, Brodmann,Area 8, Brodmann's,Brodmanns Area 8,Cortex, Frontal,Eye Field, Frontal,Eye Field, Supplementary,Eye Fields, Frontal,Frontal Cortices,Frontal Eye Field,Frontal Lobes,Lobe, Frontal,Supplementary Eye Fields
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001522 Behavior, Animal The observable response an animal makes to any situation. Autotomy Animal,Animal Behavior,Animal Behaviors
D014151 Anti-Anxiety Agents Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. Anti-Anxiety Agent,Anti-Anxiety Drug,Anxiolytic,Anxiolytic Agent,Anxiolytic Agents,Tranquilizing Agents, Minor,Anti-Anxiety Drugs,Anti-Anxiety Effect,Anti-Anxiety Effects,Antianxiety Effect,Antianxiety Effects,Anxiolytic Effect,Anxiolytic Effects,Anxiolytics,Tranquillizing Agents, Minor,Agent, Anti-Anxiety,Agent, Anxiolytic,Agents, Anti-Anxiety,Agents, Anxiolytic,Agents, Minor Tranquilizing,Agents, Minor Tranquillizing,Anti Anxiety Agent,Anti Anxiety Agents,Anti Anxiety Drug,Anti Anxiety Drugs,Anti Anxiety Effect,Anti Anxiety Effects,Drug, Anti-Anxiety,Drugs, Anti-Anxiety,Effect, Anti-Anxiety,Effect, Antianxiety,Effect, Anxiolytic,Effects, Anti-Anxiety,Effects, Antianxiety,Effects, Anxiolytic,Minor Tranquilizing Agents,Minor Tranquillizing Agents
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus

Related Publications

Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
April 1982, Neurosciences Research Program bulletin,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
February 1992, Physiology & behavior,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
June 1999, European journal of pharmacology,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
March 1992, Neuropeptides,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
August 2021, Neuropeptides,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
August 1978, Life sciences,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
November 1984, Pain,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
March 1966, Pharmacological reviews,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
January 1977, Advances in biochemical psychopharmacology,
Barbara Zieba, and Małgorzata Grzegorzewska, and Piotr Brański, and Helena Domin, and Joanna M Wierońska, and Grzegorz Hess, and Maria Smiałowska
February 2019, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
Copied contents to your clipboard!